-
-
-
-
-
-
-
Goldman Sachs Downgrades Halozyme Therapeutics (HALO) to Sell 'as we approach peak revenue'
-
-
-
-
-
-
-
Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) Provides Update on Non-Binding Proposal to Combine with Evotec (EVO)
-
-
-
-
-
-
-
HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS
-
-
-
-
-
-
-
Halozyme Provides 2023 Financial Guidance and Outlook
-
-
-
-
-
-
-
Halozyme Completes Antares Pharma Acquisition
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of Antares Pharma (ATRS)
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

